The innovative drug sector is witnessing a significant influx of industrial capital, as evidenced by a surge in share buybacks and increased holdings by company insiders. This trend is sending a strong signal of confidence in the sector's long-term prospects.

From April 1 to June 12, 2026, a total of 88 listed pharmaceutical companies on the A-share and H-share markets initiated share buyback programs. Furthermore, there were 215 announcements of increased share holdings involving 96 companies within the sector. This collective action by industrial capital marks a notable trend in the innovative drug space.

What is Driving the Surge in Buybacks and Increased Holdings?

Analysis suggests that in the current buyback wave, most of the capital is being used for employee equity incentive plans or share cancellations, aiming to protect the interests of existing shareholders. The entities increasing their holdings are primarily company executives or industrial capital, indicating insiders' recognition of the industry's enduring value. Through these tangible financial actions, management and industrial investors are demonstrating their confidence in the sector's future. This confidence is underpinned by a confluence of favorable factors, including supportive policies, market dynamics, and solid fundamentals.

Regulatory Reforms Accelerating Industry Growth

The innovative drug industry has recently benefited from a series of supportive policy measures. On May 15, the "Implementation Regulations of the Drug Administration Law of the People's Republic of China" came into effect. The general principles explicitly state that the state will improve the drug innovation system, support drug research and innovation oriented towards clinical value, encourage the research and development of new drugs, and support their clinical promotion and use.

On the market access front, the comprehensive national drug reimbursement negotiation launched on June 1 introduced a new "pre-application" channel. This mechanism allows companies with drugs that have completed technical reviews but not yet received formal approval to submit preliminary applications. This breakthrough provides new opportunities for many late-stage innovative drug companies to enter the national reimbursement drug list earlier, facilitating commercial scaling.

Robust Industry Fundamentals and Improving Profitability

In recent years, the number of out-licensing deals for China's innovative drugs has continued to increase, with a significant improvement in quality. As of June 9, 2026, domestic innovative drug companies have completed 88 out-licensing transactions year-to-date, receiving upfront payments totaling $5.0 billion. The total deal value reached $94.4 billion, with upfront payments and total deal value already reaching 70% of the full-year 2025 totals.

Driven by these industry trends, a profit inflection point for innovative drug companies is gradually emerging. Data from a sample of 57 A-share innovative drug companies shows that in 2025, their revenue and adjusted net profit attributable to the parent company grew by 10.9% and 133.4% year-over-year, respectively. For the first quarter of 2026, revenue and adjusted net profit grew by 8.4% and 39.6% year-over-year, respectively. Analysis indicates that benefiting from robust growth in core innovative drug businesses and continuous business development income recognition, leading pharmaceutical companies are expected to maintain solid performance growth for the full year 2026.

A Complete Commercial Cycle and Broad Development Prospects

Supported by national policies, China's innovative drug industry is progressively establishing a complete commercial cycle. It is anticipated that several domestically developed innovative drugs could achieve annual sales exceeding 10 billion yuan in the future, potentially unleashing the sector's full growth potential. Some institutions project that by 2035, pharmaceutical sales revenue from Chinese companies could account for approximately 1% of the country's GDP. Based on 2025 GDP figures, this translates to an overall market size potentially exceeding 1.4 trillion yuan. Supported by this industrial scale, and assuming a price-to-earnings (P/E) ratio of 20, the combined market capitalization of China's innovative drug sector could potentially rise from 2.8 trillion yuan at the end of 2025 to 13.8 trillion yuan.

How Can Investors Approach the Innovative Drug Sector?

Analysis points out that the buybacks and increased holdings by industrial capital signal recognition that the sector is near a bottom. Currently, sector valuations are at historically low levels, suggesting limited downside potential. Concurrently, the long-term policy inflection point is clear, with the industry's orientation shifting towards "supporting innovation." Based on this, institutions maintain a positive outlook on the medium- to long-term performance of the innovative drug sector.

As of June 22, 2026, the P/E ratios of the CSI Innovative Drug Index and the Hong Kong Stock Connect Innovative Drug Index were at the 47.35% and 37.81% historical percentile levels since their respective launches, indicating potential room for valuation recovery.

Investors optimistic about the long-term opportunities in the innovative drug sector can conveniently track leading companies in the A-share and Hong Kong markets through the following investment tools.

A-Share Innovative Drug Investment Tools

The Yinhua CSI Innovative Drug Industry ETF (159992) and its feeder funds (Class A: 012781; Class C: 012782) track the CSI Innovative Drug Index (931152.CSI).

Hong Kong Stock Innovative Drug Investment Tools

The Yinhua SZSE-HKEx Connect Innovative Drug ETF (159567) and its feeder funds (Class A: 023929, Class C: 023930) track the SZSE-HKEx Connect Innovative Drug Index (987018.CNI).

Risk Disclosure

Investing involves risks. Funds are long-term investment instruments primarily designed to diversify investments and reduce the specific risks associated with investing in a single security. Unlike bank deposits or other financial instruments that offer fixed return expectations, when you invest in a fund, you may share in the investment gains or bear the losses from the fund's investments.

Before making an investment decision, please read the fund's legal documents, including the fund contract, prospectus, and product summary, as well as this risk disclosure statement. Fully understand the fund's risk-return characteristics and product features, carefully consider all risk factors associated with the fund, and assess your own risk tolerance based on your investment objectives, investment horizon, experience, and financial situation. Make rational and prudent investment decisions based on your understanding of the product and appropriate sales advice.

Yinhua Fund Management Co., Ltd. provides the following risk disclosures in accordance with relevant laws and regulations:

1. Based on different investment objects, funds are categorized into equity funds, hybrid funds, bond funds, money market funds, fund of funds, commodity funds, etc. Investing in different types of funds yields different return expectations and involves varying degrees of risk. Generally, the higher the expected return of a fund, the greater the risk you assume.

2. Funds may face various risks during investment operations, including market risks, as well as management risks, technical risks, and compliance risks specific to the fund itself. Large-scale redemption risk is a unique risk of open-end funds, meaning that when the net redemption requests on a single business day exceed a certain percentage of the fund's total shares (10% for open-end funds, 20% for periodically open funds, except for special products specified by the China Securities Regulatory Commission), you may not be able to redeem all applied fund shares in a timely manner, or your redemption proceeds may be delayed.

3. You should fully understand the differences between regular fund investment plans and savings methods like fixed deposits. Regular investment plans are a simple way to guide investors towards long-term investing and averaging investment costs, but they do not eliminate the inherent risks of fund investment, guarantee investor returns, or serve as an equivalent substitute for savings.

4. Special Product Risk Disclosures:

a. Investors should be aware of the risks associated with underlying index volatility and the specific risks of ETF (Exchange Traded Fund) investment. Feeder funds invest in target ETFs; investors should be aware of the specific risks of feeder funds, including tracking deviation risk, performance divergence risk from the target ETF, other risks associated with investing in the target ETF, and the risk of failing to meet tracking error control targets.

b. The Yinhua SZSE-HKEx Connect Innovative Drug ETF and its feeder funds may invest in stocks eligible for the Hong Kong Stock Connect program, and thus face specific risks arising from differences in the investment environment, investment targets, market systems, and trading rules under the Hong Kong Stock Connect mechanism.

5. The fund manager is committed to managing and utilizing the fund's assets with honesty, diligence, and responsibility, but does not guarantee that the fund will be profitable or provide a minimum return. The fund's past performance and net asset value do not predict its future performance, and the performance of other funds managed by the fund manager does not guarantee the performance of this fund. Yinhua Fund Management Co., Ltd. reminds investors of the "buyer beware" principle in fund investment. After making an investment decision, you bear the investment risks arising from changes in the fund's operation status and net asset value. The fund manager, custodian, sales agencies, and related institutions do not make any promises or guarantees regarding fund investment returns.

6. This fund was established by Yinhua Fund Management Co., Ltd. in accordance with relevant laws and regulations and has been registered with the permission of the China Securities Regulatory Commission (hereinafter referred to as the "CSRC"). The fund's legal documents, including the fund contract, prospectus, and product summary, have been publicly disclosed on the CSRC's Fund Electronic Disclosure website (http://eid.csrc.gov.cn/fund) and the fund manager's website (www.yhfund.com.cn). The CSRC's registration of this fund does not indicate a substantive judgment or guarantee of its investment value, market prospects, or returns, nor does it indicate that investing in this fund is risk-free.